The pharmaceutical industry's new serious tone in direct-to-consumer advertising is having an unexpected effect: commercial success. While some drug categories -- like erectile dysfunction -- may be more difficult to advertise, some marketers are finding that operating within the new voluntary guidelines makes for a more effective marketing message.
By Kate Rawson
When AstraZeneca PLC retooled its direct-to-consumer advertising last year, the reasons had nothing to do with market share. Instead,...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.
The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.
